France Radiopharmaceuticals Market Size, Share, and COVID-19 Impact Analysis, By Type (Diagnostic and Therapeutic) and By Application (Neurology, Cardiology, Oncology and Others), and France Radiopharmaceuticals Market Insights, Industry Trend, Forecasts to 2035

France Radiopharmaceuticals Market Insights Forecasts to 2035 

• The France Radiopharmaceuticals Market Size was estimated at USD 746.8 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.22% from 2025 to 2035
• The France Radiopharmaceuticals Market Size is Expected to Reach USD 2178.4 Million by 2035

According to a research report published by Spherical Insights and Consulting, The France Radiopharmaceuticals Market is anticipated to reach USD 2178.4 Million by 2035, growing at a CAGR of 10.22% from 2025 to 2035. One of the main factors propelling the radiopharmaceuticals market in this area is the quick development of new radiotracers and enhanced imaging methods.

Market Overview 

The France radiopharmaceuticals market is defined as the sale of medication that includes medication with radioactive drugs as therapeutic and diagnostic agents within the France health care system. These radiopharmaceuticals or radioactive drugs are major nuclear medicine agents for staging and detection of disease and imaging of organs. The France radiopharmaceuticals market is growing immensely due to the mounting prevalence of cancer and cardiovascular disease, which require sophisticated diagnostic and therapeutic agents. Moreover, the fast growth in nuclear medicine technology, such as the discovery of new radiotracers and advanced imaging modalities, is the prime impetus for this market in the country. One of the areas of opportunity within the French market to be looked at is the expanded use of radiopharmaceutical applications beyond oncology. Infectious diseases and neurology are among the fields that are becoming increasingly trendy, presenting potential areas for growth for manufacturers and researchers alike. Personalized medicine is also opening up the potential to create tailor-made radiopharmaceuticals that adapt to patient requirements.

Report Coverage

This research report categorizes the market for the France radiopharmaceuticals market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France radiopharmaceuticals market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France radiopharmaceuticals market. 

Driving Factors

An increase in the incidence of cancer in France is a key growth driver for the France radiopharmaceuticals market. The National Cancer Institute in France stated that the number of new cancer cases is estimated to be around 500,000 by 2025, an increase of 15% compared to the previous decade. The increase in incidence of cancer calls for new diagnostics and treatment solutions that incorporate radiopharmaceuticals as part of targeted treatments, as well as diagnostic methods. The France Society of Oncology calls for additional financial investments and studies in this arena, directly contributing to increased demand for radiopharmaceuticals.

Restraining Factors

The France market for radiopharmaceuticals faces challenges such as challenging regulatory requirements that can slow down approvals and commercialization of new radiopharmaceuticals. Disposal and handling of radioactive materials are also a bit of a logistical and cost challenge, and it requires high initial capital investment to manufacture radiopharmaceuticals because of the extensive requirements for facilities. 

Market Segmentation

The France radiopharmaceuticals market share is classified into type and application.

• The diagnostic segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France radiopharmaceuticals market is segmented by type into diagnostic and therapeutic. Among these, the diagnostic segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The diagnostic segment is a vital part of the market, which facilitates accurate imaging and assessment of numerous medical ailments. This category consists of radiotracers that enable clinicians to visualize and diagnose conditions like cancer, cardiovascular diseases, and neurological impairments, resulting in appropriate and timely treatment strategies.

• The neurology segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France radiopharmaceuticals market is segmented by application into neurology, cardiology, oncology, and others. Among these, the neurology segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Radiopharmaceuticals are used in neurology applications to diagnose diseases like Parkinson's and Alzheimer's, with an increasing focus on early detection methods.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France radiopharmaceuticals market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

List of Key Companies

• IHI Corporation
• Acteon
• Lantheus Medical Imaging
• Elekta
• Cardinal Health
• Bayer
• Bracco Imaging
• Siemens Healthineers
• Thermo Fisher Scientific
• General Electric
• Valeant Pharmaceuticals
• Fujifilm
• Radiomedix
• Novartis
• Others

Recent Development 

• In April 2025, Martigny, Switzerland. Dijon, France – Debiopharm Research & Manufacturing S.A., a Swiss biopharmaceutical company dedicated to curing cancer and infectious diseases, and Oncodesign Services, a major CRO focused on drug discovery and preclinical services, report the signing of a license agreement to use the AbYlink technology for preclinical services.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France radiopharmaceuticals Market based on the below-mentioned segments:

France Radiopharmaceuticals Market, By Type         

• Diagnostic
• Therapeutic

France Radiopharmaceuticals Market, By Application       

• Neurology
• Cardiology
• Oncology
• Others